Proof of principle for epitope-focused vaccine design
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies against vulnerable epitopes. Several major pathogens have resisted traditional vaccine development, although vulnerable epitopes targeted by neutralizing antibodies have been identified for several such cases. Hence, new vaccine design methods to induce epitope-specific neutralizing antibodies are needed. Here we show, with a neutralization epitope from respiratory syncytial virus, that computational protein design can generate small, thermally and conformationally stable protein scaffolds that accurately mimic the viral epitope structure and induce potent neutralizing antibodies. These scaffolds represent promising leads for the research and development of a human respiratory syncytial virus vaccine needed to protect infants, young children and the elderly. More generally, the results provide proof of principle for epitope-focused and scaffold-based vaccine design, and encourage the evaluation and further development of these strategies for a variety of other vaccine targets, including antigenically highly variable pathogens such as human immunodeficiency virus and influenza.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous methods can scaffold functional sites made up of one or two contiguous chain segments (6–10), but with the exception of helical bundles (8) these do not extend readily to more complex sites composed of three or more chain segments, and the generated backbones are not guaranteed to be designable (encodable by some amino acid sequence).”
From Scaffolding protein functional sites using deep learning (2022) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
The global distribution and burden of dengue
Bhatt, S., Gething, P. W., Brady, O. J., Messina, J. P., Farlow, A. W., Moyes, C. L., Drake, J. M., Brownstein, J. S., Hoen, A. G., Sankoh, O., et al. (2013) · Nature · doi:10.1038/nature12060 · Cited by 10,037
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
NMR View: A computer program for the visualization and analysis of NMR data
Johnson, B. A., & Blevins, R. A. (1994) · Journal of Biomolecular NMR · doi:10.1007/bf00404272 · Cited by 3,090
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,034
Leaver-Fay (2011) · doi:10.1016/b978-0-12-381270-4.00019-6 · Cited by 1,904
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
Protein Structure Prediction Using Rosetta
Rohl, C. A., Strauss, C. E. M., Misura, K. M. S., & Baker, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)83004-0 · Cited by 1,725
Self-citationDesign of a Novel Globular Protein Fold with Atomic-Level Accuracy
Kuhlman, B., Dantas, G., Ireton, G. C., Varani, G., Stoddard, B. L., & Baker, D. (2003) · Science · doi:10.1126/science.1089427 · Cited by 1,670
Self-citation
Research works printed but not linked: 1
- Plotkin SA Orenstein WA Offit PA Vaccines 6 Elsevier 2012
Cited by
Items 301–400 of 554
Adaptation‐Proof SARS‐CoV‐2 Vaccine Design
Vishweshwaraiah, Y. L., Hnath, B., Rackley, B., Wang, J., Gontu, A., Chandler, M. R., Afonin, K. A., Kuchipudi, S. V., Christensen, N. D., Yennawar, N. H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202206055 · Cited by 13
Swegen, A., & Aitken, R. J. (2014) · Reproduction Fertility and Development · doi:10.1071/rd14280 · Cited by 13
Prisilla, A., Prathiviraj, R., & Chellapandi, P. (2017) · Journal of Molecular Evolution · doi:10.1007/s00239-017-9791-y · Cited by 15
Coronavirus epitope prediction from highly conserved region of spike protein
Yurina, V. (2020) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2020.9.2.169 · Cited by 16
“In silico studies reduce costs and time needed in developing vaccines and construct vaccines with higher efficacy and safety than conventional vaccines [5-7].”
BackgroundTargeting Viral Surface Proteins through Structure-Based Design
Narkhede, Y. B., Gonzalez, K. J., & Strauch, E. (2021) · Viruses · doi:10.3390/v13071320 · Cited by 16
Oscherwitz, J., & Cease, K. B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116882 · Cited by 14
Pinto, D., Sauer, M. M., Czudnochowski, N., Low, J. S., Tortorici, M. A., Housley, M. P., Noack, J., Walls, A. C., Bowen, J. E., Guarino, B., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.09.442808 · Cited by 15
Deciphering interaction fingerprints from protein molecular surfacesPreprint
Gaínza, P., Sverrisson, F., Monti, F., Rodolà, E., Bronstein, M. M., & Correia, B. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/606202 · Cited by 17
Self-citationDesigning an effective malaria vaccine targeting Plasmodium vivax Duffy-binding protein
Dickey, T. H., & Tolia, N. H. (2023) · Trends in Parasitology · doi:10.1016/j.pt.2023.06.011 · Cited by 21
Fan, Y., He, Y., Yin, Z., Tian, T., Shang, K., Shi, J., Shi, H., Li, Y., Zhang, F., & Wen, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1425603 · Cited by 13
“EmTSP3 exhibits a high a -helix content, while EmTIP predominantly adopts a random coil structure, which contributes to stable exposure and fl exible availability, respectively (45).”
BackgroundSelf-citationAccurate single-domain scaffolding of three nonoverlapping protein epitopes using deep learning
Castro, K. M., Watson, J. L., Wang, J., Southern, J., Ayardulabi, R., Georgeon, S., Rosset, S., Baker, D., & Correia, B. E. (2026) · Nature Chemical Biology · doi:10.1038/s41589-025-02083-z · Cited by 13
“Designer proteins displaying viral epitopes promise to improve antibody efficiency by presenting specific neutralizing epitopes to trigger specific immune responses while avoiding non-neutralizing sites with more pronounced immunodominance 11–16 .”
Self-citationAddressing Viral Resistance Through Vaccines
LAUGHLIN, C. A., Schleif, A. C., & Heilman, C. A. (2015) · Future Virology · doi:10.2217/fvl.15.53 · Cited by 13
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 12
“In this regard, the isolation of mAbs will allow precise mapping of escaping epitopes, thus allowing rational design of optimized antigens (Correia et al., 2014).”
BackgroundHarrison, T. E., Alam, N., Farrell, B., Quinkert, D., Lias, A. M., King, L. D. W., Barfod, L. K., Draper, S. J., Campeotto, I., & Higgins, M. K. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00123-0 · Cited by 13
“We identi fi ed a three-helical bundle from the E. coli ribosome recycling factor with the correct helical topology to allow epitope grafting (PDB 3LHP, chain S) which had previously been used in an epitope grafting strategy (Correia et al, 2014).”
Adamu, L., Jesse, F. F. A., Idris, U. H., Odhah, M. N., Arsalan, M., Muhammad, N. A., Bhutto, K. R., Peter, I. D., Abraham, G. A., Wahid, A. H., et al. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.039 · Cited by 12
Prisilla, A., Prathiviraj, R., Sasikala, R., & Chellapandi, P. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.06.029 · Cited by 12
Janahi, E. M. A., Dhasmana, A., Srivastava, V., Sarangi, A. N., Raza, S., Arif, J. M., Bhatt, M. L. B., Lohani, M., Areeshi, M. Y., Saxena, A. M., et al. (2017) · EXCLI journal · doi:10.17179/excli2016-719 · Cited by 12
“Also, in the recent past, the epitope based vaccines have given promising results against highly infectious diseases such as H1N1, HIV and Tuberculosis (Correia et al., 2014) .”
H1N1 influenza virus epitopes classified by monoclonal antibodies
Guo, C., Zhang, H., Xie, X., Liu, Y., Sun, L., Li, H., Yu, P., Hu, H., Sun, J., Li, Y., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6429 · Cited by 12
“As epitopes are a key feature of viruses, several strategies have been successfully applied in the design and development of ‘epitope-focused’ vaccines (23,24), which demonstrate advantages such as high specificity, fewer side effects, simple preparation, and easy storage and transportation (25,26).”
Self-citationLiu, Z., Yang, X., Duan, C., Li, J., Tong, R., Fan, Y., Feng, J., Cao, R., Zhong, W., Feng, X., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0183-1 · Cited by 14
Soluble cysteine‐rich tick saliva proteins Salp15 and Iric‐1 fromE. coli
Kolb, P., Vorreiter, J., Habicht, J. L., Bentrop, D., Wallich, R., & Nassal, M. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.12.002 · Cited by 15
Padhi, A. K., Kalita, P., Zhang, K. Y. J., & Tripathi, T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.19.104042 · Cited by 14
Jin, J., Bai, Y., Zhang, Y., Lu, W., Zhang, S., Zhao, X., Sun, Y., Wu, Y., Zhang, A., Zhang, G., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127311 · Cited by 11
Tang, W. K., Salinas, N. D., Kolli, S. K., Xu, S., Urusova, D. V., Kumar, H., Jimah, J. R., Subramani, P. A., Ogbondah, M. M., Barnes, S. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51701-2 · Cited by 14
“Thisprocessreliesonidentifyingneutralizing and non-neutralizing epitope maps in antigens 15,33,50 – 58 and applying this information to design immunogens that elicit protective antibody responses 49,59 – 65 .”
Deciphering the human immunome
Crowe, J. E., & Koff, W. C. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1082427 · Cited by 11
“As such, the Project has proposed a flagship program, Human Immunome Program to define the sequence of all of these molecules, providing a definitive road map for design of new vaccines optimally configured to use the immune molecules available in humans to respond to vaccines [3].”
BackgroundSelf-citationRegenmortel, M. H. V. V., & CNRS, U. I. D. R. D. L. D. B. D. S. (. (2015) · AIMS Public Health · doi:10.3934/publichealth.2015.2.183 · Cited by 11
Broadly neutralizing antibodies for therapy of viral infections
Varadarajan, R., Srinivasan, S., Maity, S., & Ghosh, M. (2016) · Antibody Technology Journal · doi:10.2147/anti.s92190 · Cited by 11
“107 In addition, bNAbs can potentially be used for therapy, preferably for acute conditions where viral escape is unlikely.”
Staged heterogeneity learning to identify conformational B-cell epitopes from antigen sequences
Ren, J., Song, J., Ellis, J., & Li, J. (2017) · BMC Genomics · doi:10.1186/s12864-017-3493-0 · Cited by 11
“B-cell epitopes are able to stimulate B-cells to produce neutralizing antibodies, and can be used to design safe vaccines, especially for vulnerable populations such as infants, young children and the elderly, to be immunized against infectious diseases [2].”
BackgroundA Framework to Simplify Combined Sampling Strategies in Rosetta
Porter, J. R., Weitzner, B. D., & Lange, O. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138220 · Cited by 11
“That said, this approach is viable in many cases, and has been used to great effect in state-of-the-art prediction[4,17,18] and design[6,7,11,19] simulations in Rosetta, as well as in other software suites like HADDOCK[17] and IMP[14].”
MethodSAGE: A Fast Computational Tool for Linear Epitope Grafting onto a Foreign Protein Scaffold
Capelli, R., Marchetti, F., Tiana, G., & Colombo, G. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00584 · Cited by 11
Decoupling peptide binding from T cell receptor recognition with engineered chimeric MHC-I molecules
Papadaki, G. F., Ani, O., Florio, T. J., Young, M. C., Danon, J. N., Sun, Y., Dersh, D., & Sgourakis, N. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1116906 · Cited by 12
“Frontiers in Immunology 13 focused vaccination strategies are based on eliciting antibodies towards non-immunogenic antigens with multiple applications against diseases and cancer therapy (69, 70).”
BackgroundMorales, J. F., Yu, B., Perez, G., Mesa, K. A., Alexander, D. L., & Berman, P. W. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.07.003 · Cited by 11
Gaines, J. C., Virrueta, A., Buch, D. A., Fleishman, S. J., O’Hern, C. S., & Regan, L. (2017) · Protein Engineering Design and Selection · doi:10.1093/protein/gzx011 · Cited by 11
“A grand challenge in biology is to design new protein–protein interactions for many potential applications including point of care diagnostics (Rusling et al., 2010), sensors for proteinaceous biological warfare agents (Sapsford et al., 2008) and more effective vaccines (Correia et al., 2014).”
BackgroundIntegrating linear optimization with structural modeling to increase HIV neutralization breadth
Sevy, A. M., Panda, S., Crowe, J. E., Meiler, J., & Vorobeychik, Y. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005999 · Cited by 12
Self-citationAsymmetric protein design from conserved supersecondary structures
ElGamacy, M., Coles, M. P., & Lupas, A. N. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.10.010 · Cited by 12
Kumar, R., Maji, S., Tiwari, S., Misra, J. P., Gupta, J., Kumar, N., Gupta, R., & Jha, N. K. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117349 · Cited by 11
Efficient protein structure generation with sparse denoising models
Jendrusch, M., & Korbel, J. O. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-01100-z · Cited by 10
“Methods capable of solving these design tasks enable powerful applications in basic research and industry, for example, designing or optimizing enzymes 14–16 , antibodies 8 , vaccine scaffolds 17,18 and biosensors 12 .”
MUNIKANNAIAN, R., Upendra, R. S., & Nagar, S. S. (2022) · The Eurasia Proceedings of Science Technology Engineering and Mathematics · doi:10.55549/epstem.1222685 · Cited by 10
“…et al. 2021, Fadhil & Jaleel, 2022), epitope mapping of viral pandemics (Sikora et al. 2021, Colitti et al. 2022), Epitopefocused vaccine design to develop novel drugs (Correia et al. 2014 & Hussein et al. 2021) is the possible approach to develop novel drugs to fight against the global pandemics”
BackgroundWhat Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?
Lu, H. J., Cheng, Z., Hu, Y., & Tang, L. V. (2023) · Biology · doi:10.3390/biology12020166 · Cited by 10
Tran, M. H., Martina, C. E., Moretti, R., Nagel, M., Schey, K. L., & Meiler, J. (2025) · Journal of Structural Biology · doi:10.1016/j.jsb.2025.108166 · Cited by 11
“More specifically, insights into the molecular mechanisms of Ab recognition of viral epitopes, derived from these structures, can guide rational vaccine design by focusing efforts on key epitopes (Burton, 2017; Correia et al., 2014; Martina et al., 2023; Rappuoli et al., 2016).”
Antibodies Targeting the Envelope of HIV-1
Mayr, L. M., & Zolla‐Pazner, S. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0025-2014 · Cited by 10
Liao, H., Shi, Z., Zhou, G., Luo, J., Wang, W., Feng, L., Zhang, F., Shi, X., Tian, H. W., & Zheng, H. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13146-x · Cited by 10
“…of viral protein is increasingly used to contribute to vaccine design and distinguish between mAbs, so as to provide a basis for the establishment and optimization of diagnostic methods (Sotelo et al. 2011; Correia et al. 2014; Fleri et al. 2017; Parvizpour et al. 2020; De-Simone et al. 2021).”
BackgroundOscherwitz, J., Muñoz-Planillo, R., Yu, F., Núñez, G., & Cease, K. B. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.03.012 · Cited by 10
Liu, Y., Lin, C.-Y., & Hong, H.-M. (2017) · International Journal of Pharmacology · doi:10.3923/ijp.2017.122.133 · Cited by 10
Golshani, M., Oloomi, M., & Bouzari, S. (2017) · In Silico Pharmacology · doi:10.1007/s40203-017-0022-4 · Cited by 10
“Peptide vaccines have advantages for their chemical stability, absence of infectious potential, and ease of construction and production (Sette and Fikes 2003; Correia et al. 2014).”
BackgroundChang, J., Zhang, Y., Yang, D., Jiang, Z., Wang, F., & Li, Y. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001194 · Cited by 12
Self-citationNagarathinam, K., Scheck, A., Labuhn, M., Stroh, L. J., Herold, E., Veselková, B., Tune, S., Cramer, J., Rosset, S., Vollers, S. S., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado2600 · Cited by 11
Self-citationKlenchin, V. A., Clark, N. M., Keles, N. K., Capuano, S., Mason, R. D., Gao, G., Broman, A. T., Köse, E., Immonen, T. T., Fennessey, C. M., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adq4973 · Cited by 10
Protein nanocages: A new frontier in mucosal vaccine delivery and immune activation
Lavanya Agnes Angalene, J., Pa, P., Seng, C. Y., Rhee, J. H., & Lee, S. E. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2492906 · Cited by 11
Bio-imprinted materials towards artificial antibodies: Technique, application and perspective
Liu, L., Liu, J., Zhang, W., Liang, Z., Zhang, Y., Liu, J., Yang, K., & Zhang, L. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118453 · Cited by 9
Proceeding artificial intelligence technology towards vaccine designs
Zhao, F., & Zai, X. (2025) · The Innovation Life · doi:10.59717/j.xinn-life.2025.100162 · Cited by 9
Achievements and Challenges in Computational Protein Design
Samish, I. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6637-0_2 · Cited by 11
“In 2014 the Schief lab collaborated with Baker and others to apply CPD for the important cause of epitope-focused vaccine design [116].”
MethodFocused dengue vaccine development: outwitting nature's design
Kudlacek, S. T., & Metz, S. (2019) · Pathogens and Disease · doi:10.1093/femspd/ftz003 · Cited by 9
virusMED: an atlas of hotspots of viral proteins
Zhang, H., Chen, P., Ma, H., Woińska, M., Liu, D., Cooper, D. R., Peng, G., Peng, Y., Deng, L., Minor, W., et al. (2021) · IUCrJ · doi:10.1107/s2052252521009076 · Cited by 9
Koff, W. C. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.03.007 · Cited by 9
Chick, J. A., Abongdia, N. N., Shey, R. A., & Apinjoh, T. O. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42014 · Cited by 8
“In recent years, reverse vaccinology coupled with immuno-informatics has revolutionized vaccine development, leveraging vast databases and tools to design safer and more efficacious multi-epitope vaccines [11,12].”
Bekkering, E. T., Yoo, R., Hailemariam, S., Heide, F., Ivanochko, D., Jackman, M. J., Proellochs, N. I., Stoter, R., van Gemert, G., Maeda, A., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.014 · Cited by 14
Designing multivalent immunogens for alphavirus vaccine optimization
Read, C. M., Plante, K. S., Rafael, G. H., Rossi, S. L., Braun, W. A., Weaver, S. C., & Schein, C. H. (2021) · Virology · doi:10.1016/j.virol.2020.11.010 · Cited by 8
Padhi, A. K., Kalita, P., Maurya, S., Poluri, K. M., & Tripathi, T. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04542 · Cited by 9
Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display
Guo, N., Duan, H., Kachko, A. V., Krause, B. W., Major, M. E., & Krause, P. R. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.021 · Cited by 10
Workshop report: Experimental animal models for universal influenza vaccines
D’Alessio, F., Koopman, G., Houard, S. A., Remarque, E. J., Stockhofe, N., & Engelhardt, O. G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.024 · Cited by 9
Rose, A. H., Hoffmann, F. W., Hara, J. H., Urschitz, J., Moisyadi, S., Hoffmann, P. R., & Bertino, P. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1047567 · Cited by 8
Perspectives on novel vaccine development
Wang, Y. B., Wang, L. P., & Li, P. (2018) · Polish Journal of Veterinary Sciences · doi:10.24425/124302 · Cited by 10
“…of a neutralizing antibody motavizumab (mota) in complex with its epitope from the respiratory syncytial virus (RSV) fusion (F) glycoprotein, Correia et al. (2014) designed epitope-scaffold immunogens with a helix-turn-helix conformation using a computational method which allowed de novo…”
MethodWang, Y., Hu, D., Wu, Y., & Ying, T. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0764-y · Cited by 8
RosettaSurf—A surface-centric computational design approach
Scheck, A., Rosset, S., Defferrard, M., Loukas, A., Bonet, J., Vandergheynst, P., & Correia, B. E. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009178 · Cited by 8
“In recent years, protein design has shown promising results in the field of immunoengineering, allowing the computational design of epitope-focused immunogens that were shown to elicit functional antibody responses in mice and non-human primates (34,36,37,42).”
BackgroundSelf-citationLatest options for treatment of bronchiolitis in infants
Vandini, S., Faldella, G., & Lanari, M. (2016) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2016.1157473 · Cited by 8
Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motifPreprint
Hauser, B. M., Sangesland, M., Denis, K. S., Windsor, I. W., Feldman, J. E., Lam, E. C., Kannegieter, T., Balazs, A. B., Lingwood, D., & Schmidt, A. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.15.435440 · Cited by 8
“53 Two immunogen design strategies used to direct humoral responses include “masking” epitopes 54 via engineering putative N-linked glycosylation sites (PNGs) and the design of protein scaffolds 55 to present broadly protective epitopes (12, 13); these strategies have been used previously for viral 56 glycoproteins RS…”
Improved motif-scaffolding with SE(3) flow matching
Yim, J., Campbell, A., Mathieu, É., Foong, A. Y. K., Gastegger, M., Jiménez-Luna, J., Lewis, S., Satorras, V. G., Veeling, B. S., Noé, F., et al. (2024) · Transactions on machine learning research · doi:10.48550/arxiv.2401.04082 · Cited by 78
“Motif-scaffolding is widely used, with applications to vaccine and enzyme design (Procko et al., 2014; Correia et al., 2014; Jiang et al., 2008; Siegel et al., 2010).”
Tan, Z., Yang, C., Lin, P., Ramadan, S., Yang, W., Rashidi, Z., Lang, S., Shafieichaharberoud, F., Gao, J., Pan, X., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302755 · Cited by 8
Atomic molecular dynamics simulation advances of de novo-designed proteins
Meng-Jiao, W. A. N. G., Ma, A., Wang, H.-J., & Lou, X. (2024) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583524000131 · Cited by 9
“…that computational protein design could produce small, thermally and conformationally stable protein scaffolds with a neutralization epitope from respiratory syncytial virus, accurately mimicking the viral epitope structure and induce potent neutralizing antibodies (Correia et al. , 2014).”
Yang, Y., Wang, R., Guo, F., Zhao, T., Lei, Y., Yang, Q., Zeng, Y., Yang, Z., Ajavavarakula, T., Tan, R., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-01059-9 · Cited by 9
Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design
Hauser, B. M., Feldman, J. E., Sangesland, M., Ronsard, L., Denis, K. S., Sheehan, M. L., Cao, Y., Boucau, J., Windsor, I. W., Cheng, A. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100834 · Cited by 6
“36–38 Here, we used an immunogen design strategy to re-direct pre-existing antibody responses toward conserved epitopes by engineering putative N-linked glycosylation sites to ‘‘mask’’ undesirable epitopes.”
Towards an anti-disease malaria vaccine
Lennartz, F., Lavstsen, T., & Higgins, M. K. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170091 · Cited by 7
Lai, J. I., Verma, D., Bailey‐Kellogg, C., & Ackerman, M. E. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy010 · Cited by 7
“…probes utilize structural information of antibody (Ab):antigen recognition to present epitopes against which particularly potent or broadly neutralizing Ab (bnAb) responses develop (Kulp and Schief, 2013; McLellan et al., 2013; Correia et al., 2014; Impagliazzo et al., 2015; Rappuoli et al., 2016).”
BackgroundWoolums, A. R., & Swiderski, C. (2021) · Current Issues in Molecular Biology · doi:10.21775/cimb.042.605 · Cited by 11
Rational design of TNFα binding proteins based on the de novo designed protein DS119
Zhu, C., Zhang, C., Zhang, T., Zhang, X., Shen, Q., Tang, B., Liang, H., & Lai, L. (2016) · Protein Science · doi:10.1002/pro.3029 · Cited by 7
Bozhanova, N. G., Flyak, A. I., Brown, B. P., Ruiz, S. E., Salas, J. H., Rho, S., Bombardi, R. G., Myers, L., Soto, C. S., Bailey, J. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30865-9 · Cited by 6
Self-citationDe novo protein design enables precise induction of functional antibodies in vivoPreprint
Sesterhenn, F., Yang, C., Bonet, J., Cramer, J., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/685867 · Cited by 7
Self-citationEpitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold
Zhao, F., Zhang, Y., Zhang, Z., Chen, Z., Wang, X., Wang, S., Li, R., Li, Y., Zhang, Z., Zheng, W., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03200-9 · Cited by 9
Self-citationRecent Advances in Bioconjugate Vaccine Development
Wren, B. W., Hall, C. L., Terra, V. S., Harrison, M. A., Atkins, E., Nasher, F., & Passmore, I. J. (2025) · Vaccines · doi:10.3390/vaccines13070703 · Cited by 9
Zhang, X., Ge, S., Wang, Y., Wang, M., Xu, Y., Chen, Y., Song, Z., Zhao, L., Zhang, J., Qi, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr7464 · Cited by 7
Duan, Y., Tang, X., Liu, S., Cui, W., Li, M., tang, S., Yao, W., Li, W., Weng, J., Zhao, J., et al. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13348-3 · Cited by 7
NIAID Workshop Report: Systematic Approaches for ESKAPE Bacteria Antigen Discovery
Sastalla, I., Kwon, K., Huntley, C. C., Taylor, K. L., Brown, L. L., Samuel, T., & Zou, L. (2025) · Vaccines · doi:10.3390/vaccines13010087 · Cited by 7
“…rely on bacterial polysaccharides conjugated to a carrier protein, and more easily manufactured alternatives, such as bioconjugated and multiple antigen-presenting systems (MAPSs), were discussed, some of which have already been tested and developed for select ESKAPE pathogens [54,59–61].”
Remmel, J. L., Beauchemin, K. S., Mishra, A. K., Frei, J. C., Lai, J. R., Bailey‐Kellogg, C., & Ackerman, M. E. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00073 · Cited by 6
Step‐by‐step design of proteins for small molecule interaction: A review on recent milestones
Pereira, J. M. R., Vieira, M., & Santos, S. M. (2021) · Protein Science · doi:10.1002/pro.4098 · Cited by 9
“…(2015) SR Targeted SSD Cell-based Yes 22 Taylor et al. (2016) SR Targeted FB Cell-based Yes 23 Wijma et al. (2015) SR Targeted FB Cell-based No 24 Correia et al. (2014) FR Targeted FB Cell-based No 25 Eisenbeis et al. (2012) FR - SSD Cell-based No 26 Jacobs et al. (2016) FR - SSD Cell-based No…”
BackgroundSadeghi, S., Bandehpour, M., Hoseini, M. H. M., & Sharifnia, Z. (2021) · PubMed Central · doi:10.22038/ijbms.2021.58087.12909 · Cited by 6
“Epitope mapping is an appropriate approach for virtual screening of amino acid sequences of virulent proteins of pathogens to predict their antigenic and immunogenic regions (epitope) (12, 13).”
BackgroundMullen, T. E., Abdullah, R., Boucher, J., Brousseau, A., Dasuri, N. K., Ditto, N. T., Doucette, A. M., Emery, C., Gabriel, J., Greamo, B., et al. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab018 · Cited by 7
Fragoso-Saavedra, M., Ramírez-Estudillo, C., Peláez-González, D. L., Ramos-Flores, J. O., Torres-Franco, G., Núñez-Muñoz, L. A., Marcelino-Pérez, G., Segura-Covarrubias, M. G., González‐González, R., Ruíz‐Medrano, R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.848054 · Cited by 7
“In this context, epitope-based vaccine design is an attractive method to elicit nAbs to conserved, relevant, but non-immunodominant B-cell epitopes in emerging and re-emerging viruses (44, 45).”
MethodShi, X., Zheng, J., & Yan, T. (2018) · Journal of Molecular Modeling · doi:10.1007/s00894-018-3613-z · Cited by 6
Ramamurthy, M., Sankar, S., Abraham, A. M., Nandagopal, B., & Sridharan, G. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29017 · Cited by 6
A Rosetta-based protein design protocol converging to natural sequences
Sormani, G., Harteveld, Z., Rosset, S., Correia, B. E., & Laio, A. (2021) · The Journal of Chemical Physics · doi:10.1063/5.0039240 · Cited by 7
Self-citationImmune Human Antibody Libraries for Infectious Diseases
Chan, S. K., & Lim, T. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_4 · Cited by 7
Accelerating therapeutic protein design
ElGamacy, M. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.01.004 · Cited by 6
Cook, J. D., Khondker, A., & Lee, J. E. (2022) · Communications Biology · doi:10.1038/s42003-022-03235-w · Cited by 10
Antibody Engineering and Therapeutics: December 8-12, 2013, Huntington Beach, CA
Almagro, J. C., Gilliland, G. L., Breden, F. J., Scott, J. K., Sok, D., Pauthner, M. G., Reichert, J. M., Helguera, G. F., Andrabi, R., Mabry, R., et al. (2014) · mAbs · doi:10.4161/mabs.28421 · Cited by 7
Self-citationZubair, A., Ali, M. F., Al-Emam, A., & Elmagzoub, R. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-18828-8 · Cited by 6
Tian, Y., Zhang, M., Ali, S. L., Abduldayeva, A. A., Zhou, S., An, Y., Li, Y., Ni, R., Zhang, L., Liu, Y., et al. (2026) · Pathogens · doi:10.3390/pathogens15030297 · Cited by 5
“This proportion ensures structural stability while allowing sufficient epitope exposure [82–84].”
Self-citationMcCarthy, M., Villafana, T. L., Stillman, E. A., & Esser, M. T. (2014) · Future Virology · doi:10.2217/fvl.14.60 · Cited by 5
Host Defense Mechanisms Against Viruses
Crowe, J. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-35214-7.00122-0 · Cited by 5
Self-citationReovirose aviária: um panorama
Assunção, T. R. D. S., Palka, A. P. G., & Pavoni, D. P. (2018) · Revista de Educação Continuada em Medicina Veterinária e Zootecnia do CRMV-SP · doi:10.36440/recmvz.v16i2.37781 · Cited by 5
Elalouf, A., & Yaniv‐Rosenfeld, A. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00560-3 · Cited by 6
“Utilizing epitopes that have been mapped for constructing a vaccine is an advanced approach to eliciting an immune response against infectious agents [91].”
Background
Metadata
- Authors
- Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., Connell, M. J., Stevens, E., Schroeter, A., Chen, M., MacPherson, S., Serra, A. M., Adachi, Y., Holmes, M. A., Li, Y., Klevit, R. E., Graham, B. S., Wyatt, R. T., Baker, D., Strong, R. K., Crowe, J. E., Johnson, P. R., & Schief, W. R.
- Affiliations
- Scripps Research Institute (US)
- Vanderbilt University Medical Center (US)
- Children's Hospital of Philadelphia (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- National Institutes of Health (US)
- Corresponding author
- Schief, William R.
- ORCID
- Venue
- Nature
- Published
- 2014-02-05
- Volume
- 507
- Issue
- 7491
- Pages
- 201-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4260937
- OpenAlex
- W2040299410
- Cited by
- 555
- References
- 38
- Citations by year
- 2026: 39 · 2025: 40 · 2024: 37 · 2023: 32 · 2022: 55 · 2021: 44 · 2020: 43 · 2019: 45 · 2018: 40 · 2017: 47 · 2016: 50 · 2015: 52 · 2014: 30
- FWCI
- 24.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc)
- PubMed Central (acceptedVersion, cc-by-nc)
- Funders
- Bill and Melinda Gates Foundation
- International AIDS Vaccine Initiative
- March of Dimes Foundation
- Children's Hospital of Philadelphia
- University of Washington
- National Institutes of Health
- Center for AIDS Research, University of Washington
- University of California, San Diego
- National Cancer Institute (T32CA080416)
- National Institute of General Medical Sciences (T32GM007270)
- National Institute of Allergy and Infectious Diseases (P30AI 36214, U54AI057141, U54 AI 005714, R01AI102766, UM1AI100663, R21AI088554, P01AI094419, P30AI036214, P30AI045008)
- Center for AIDS Research, University of California, San Diego
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- RSV vaccine, neutralizing antibodies, computational protein design, protein scaffolds, antigenic determinants, vaccine development
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Antigens, Viral, Enzyme-Linked Immunosorbent Assay, Macaca mulatta, Male, Mice, Inbred BALB C, Models, Molecular, Neutralization Tests, Protein Conformation, Respiratory Syncytial Viruses, Drug Design, Crystallography, X-Ray, Amino Acid Motifs, Respiratory Syncytial Virus Vaccines, Mice, Protein Stability, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.